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Abstract
Background: Traditional and complementary medicines (T&CM) are any form of medicine, practice, treatment,
product, technology, knowledge system or ceremony outside of conventional medical practice that aims to prevent
and/or treat illness and/or promote well-being. Alongside conventional cancer treatments, T&CM usage is
increasing; with 19% of indigenous Australians with cancer reporting using T&CM. There is limited evidence
surrounding T&CM use and disclosure by indigenous patients. Our aim was to explore healthcare providers’ views
about usage, disclosure/non-disclosure of T&CM by Indigenous cancer patients.
Methods: Semi-structured, in-depth interviews with 18 healthcare providers, including three indigenous providers,
at a large urban hospital providing care to Indigenous cancer patients were conducted to explore providers’
experiences and attitudes towards T&CM use by Indigenous cancer patients. An interpretive phenomenological
approach was used to thematically analyse the data.
Results: Analysis revealed six themes: concern about risk; no ‘real’ benefits; perception of T&CM and conventional
medicine as antithetical; barriers to disclosure; ‘patients’ choice’ a double-edged sword; and providers’ lack of
knowledge about T&CM. Healthcare providers perceived discord between T&CM and conventional medicine. Most
lacked knowledge of T&CM, and had concerns around negative-interactions with conventional treatments. They
considered T&CM outside their role, citing this as reasoning for their lack of knowledge. Indigenous healthcare
providers had greater understanding and openness towards T&CM.
Conclusions: Given the potential usage of T&CM by Indigenous cancer patients, providers need a more
comprehensive understanding of T&CM in order to inform discussion and facilitate effective disclosure on this topic.
If indigenous Australians with cancer feel that cancer care providers are unreceptive to discussing T&CM, patient
care risks being compromised; particularly given the potential for negative interactions between T&CM and
conventional cancer treatments. Fostering health care interactions where indigenous patients feel comfortable to
discuss T&CM usage should be a priority for all cancer care services.
Keywords: Aboriginal people, Cancer, Cancer care, Complementary medicine, Indigenous medicine, Traditional
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Background
Australian cancer patients in general have one of the
highest survival rates in the world; however, this is not
so for all groups of Australian cancer patients [1]. Can-
cer is the second leading cause of mortality among Abo-
riginal and Torres Strait Islander Australians (hereafter
respectfully referred to as indigenous Australians), and
most concerning is the cancer mortality gap between in-
digenous and non-indigenous Australians, which is in-
creasing (1998–2015; 21% of indigenous vs 13% of non-
indigenous) [1]. While reasons for this disparity are
complex, there is evidence that factors such as advanced
cancer stage at diagnosis [2–4], reduced access to, up-
take and/or completion of treatment [3, 5–8], and higher
rates of co-morbidities [3, 7] amongst indigenous pa-
tients contribute to their poorer cancer outcomes rela-
tive to non-indigenous Australians. Indigenous people
tend to have a holistic concept of health, which contrasts
with the biomedical model [9, 10]. This differing per-
spective incorporates their need for connection to cul-
ture, heritage, land and the spirits of their ancestors,
which alongside the social and spiritual support that
traditional healer’s provide, is seen as highly important
to indigenous people [9, 10]. It is therefore likely that
traditional and complementary medicine (T&CM) plays
an important role in re-establishing wellness for Indigen-
ous cancer patients, rather than solely focussing on cur-
ing the disease.
The use of T&CM alongside conventional cancer treat-
ments such as chemotherapy and radiotherapy is increasing
[11, 12]. Traditional Medicine (TM) and Complementary
Medicine (CM) [14] include a broad range of practices,
technologies, products, knowledge systems and approaches
to preventing and/or treating illness and/or promoting
well-being that are not historically associated with conven-
tional medicine [13]. While TM refers to health care that is
indigenous to the local culture of users (including treat-
ments such as herbal medicines and practices provided by
traditional indigenous healers), CM refers to health care,
both self-administered or practitioner-led, which is often
exotic to the culture of users (examples for indigenous
Australians include massage, chiropractic and western
herbal medicine) [14]. Essentially, both TM and CM are
treatments provided to people outside of conventional
medical practice. Whether a treatment is regarded as TM
or CM is dependent on the culture and context of the user
and the use [15].
A holistic approach to healthcare is fundamental to
the health and wellbeing of indigenous Australians
[16]. Indigenous Australians tend to view health from
a holistic standpoint, which encompasses their indi-
vidual spiritual, emotional and cultural needs [16–
18]. This view extends beyond the physical to a
whole of person approach, and beyond the individual
to encompass their family, community and environ-
ment [16–18]. CM is also underpinned by a model
of holism, which may be why indigenous people who
lack access to TM may choose to make use of avail-
able CM alternatives. Moreover, as with all cultures,
indigenous Australian culture is continually evolving
and many indigenous Australians also identify other
cultural groups. This makes the line between TM
and CM unclear and largely superfluous. For these
reasons, it was important to include CM in our dis-
cussions with providers, as their Indigenous cancer
patients are potentially using CM, TM or T&CM.
There is a dearth of evidence relating to the use of
T&CM among Indigenous cancer patients. In a 2015
study conducted by Adams and colleagues in Queens-
land, 18.7% of indigenous Australian cancer patients
used at least one form of T&CM for support with their
care [19]. Furthermore, there is evidence that some
herbs and nutritional supplements can upregulate en-
dogenous antioxidants that negate the effects of chemo-
therapy drugs [20–22]. This potential for risk has
contributed to a stark divide between healthcare pro-
viders’ views on T&CM use alongside conventional can-
cer medicine [23–25]. Broom and Adams found
oncology consultants used ‘risk’ as a means to discour-
age T&CM use by cancer patients, and that they held
the view that the main drivers of patients to use T&CM
were ‘irrationality’, ‘seeking control’ and ‘desperation’
[25]. These findings highlight potential barriers for can-
cer patients to disclose their use of T&CM with their
healthcare providers [25].
The importance of open and effective patient-clin-
ician communication is paramount in modulating the
potential risks and benefits associated with the use of
T&CM in the cancer setting [25, 26]. The communi-
cation gap between healthcare providers and indigen-
ous Australians has a significant impact on health
outcomes [27–30]. Cass and colleagues used qualita-
tive methods to observe both healthcare providers
and indigenous renal patient communicative interac-
tions, along with face-to-face interviews, to explore
factors that may lead to ineffective communication in
clinical settings [27]. They found that there was rarely
a shared understanding of the key concepts involved
in the patients’ healthcare, and that this miscommuni-
cation often went unnoticed. Similar findings were re-
ported in a study by Lowell and colleagues where
interviews with indigenous chronic disease patients
revealed that patients felt they were not receiving the
detailed information about their healthcare they
needed and that the information was willingly being
withheld from them [28]. These findings highlight
how pervasive clinical miscommunication can be with
indigenous patients and non-indigenous providers,
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which undermines trust in the patient-clinician rela-
tionship which is vital to the success of healthcare
[28].
A handful of studies have identified factors that hinder
patient-clinician communication with indigenous Aus-
tralian cancer patients. These factors include healthcare
providers self-reporting that they struggled to communi-
cate with their Indigenous cancer patients, especially
when English was the patients’ second or third language
[26]. This is concerning given that healthcare providers
in the cancer-care setting often convey complex infor-
mation to their patients that is imperative to their care
[26]. Meiklejohn and colleagues found that healthcare
providers reported difficulties in understanding Indigen-
ous cancer patients’ worldviews and the complexity be-
hind their connection to land and family [26]. This
finding corresponds with Shahid and colleagues that In-
digenous cancer patients felt healthcare providers ig-
nored the importance of their connections to land and
family, which contributed to the breakdown of trust in
the clinical relationship [31]. Other factors that affect
patient-clinician communication include the constrains
around appointment times, with lack of time being seen
by the healthcare providers as a significant barrier to ef-
fective communication [26].
Understanding healthcare providers’ knowledge and
understanding of T&CM use among their Indigenous
cancer patients, and their openness to patient disclosure
of T&CM use, is an important first step in building an
evidence base in this area [31]. The aim of this study is
to explore healthcare providers’ experiences and per-
spectives relating to usage, disclosure and non-disclosure
of T&CM by Indigenous cancer patients. Indeed, explor-
ing the cancer-care setting that Indigenous cancer pa-
tients experience will provide insight into the possible
barriers and facilitators they face when making decisions
around disclosure and non-disclosure of T&CM use
with healthcare providers.
Methods
Participants and data collection
We employed purposive sampling to ensure we captured
views on use and disclosure of T&CM from a broad
range of healthcare roles at a large urban hospital in
Queensland. Inclusion criteria was any healthcare pro-
viders (e.g. social workers, nurses, oncologists) involved
in the care of Aboriginal and Torres Strait Islander can-
cer patients. Once identified, the providers were initially
informed about the study by a clinical nurse consultant,
who then informed the study group of any providers
who had shown an interest in being involved in the
study. Upon contacting the providers again, those who
indicated a willingness to participate in the study were
then contacted by an experienced study interviewer to
organise a time to meet. The interviewer confirmed in
person with the provider their willingness again to par-
ticipate, gained their formal consent and then conducted
the interview. Data collection was undertaken from No-
vember 2016 to May 2017.
Study design
The study employed qualitative research methods and
the interviews were guided by a semi-structured inter-
view schedule. The interview schedule was initially
assessed and amended for flow, wording and ease of use
in mock interviews with non-providers. It was then pilot
tested with one provider for clarity of content and ap-
propriate terminology. No changes were made to the
schedule following this pilot interview, and the data
from this interview was included in the current analysis.
The interview schedule also included a definition of
T&CM (Complementary and Alternative medicines (or
CM) refer to any therapies, medicines, herbal and nutri-
tional supplements that sit outside of the dominant
health system. For example, meditation, Homeopathy,
Naturopathy, Traditional Chinese Medicine. Traditional
Aboriginal Medicines include the use of singing/chanting,
bush medicine, traditional healers and external remedies
prepared for healing or prevention purposes) and a broad
outline of topics to be discussed, but also allowed the
providers ample opportunity to both describe and ex-
plain their experiences and perceptions in their own
words and on their own terms as well as introduce new
topics for discussion.
Interviews were undertaken face-to-face and all inter-
views were audio recorded with the providers consent.
Field notes were taken where relevant. Basic demo-
graphic information was also collected from the pro-
viders relating to their ethnicity, sex, job role, and length
of time they had worked in the role.
Data analysis
All interviews were transcribed verbatim, de-identified
and checked for accuracy and imported into NVivo11
[32] for analysis. As data coder (AG) has previous know-
ledge of T&CM, we introduced a second data coder
(KA) with no prior knowledge of this area, by doing this
and by undertaking the following process, we were able
to reduce expert bias and therefore strengthen the valid-
ity of our analysis. Each transcript was independently
read by two data coders (AG and KA). Major themes
were identified through an iterative process and exam-
ples were documented separately by each coder. Concept
maps were used to compare and contrast categories
throughout the research process and to consolidate
these categories into themes that related to the research
aims. The coders (AG and KA) collaboratively negoti-
ated themes into a common final set to be analysed.
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Using these themes the coders (AG and KA) made quote
selections, ensuring the most illustrative quotes covering
all provider views were used. The interview content in
each of these themes was analysed using an interpretive
phenomenological analysis approach [33], which offers
insights into the “lived experience” of the participants
and an understanding of how people make sense of a
phenomenon within a given context. Identified themes
and quote selections were verified by a third independ-
ent coder (GG).
Ethical considerations
Ethical approval was obtained from the Northern Terri-
tory Department of Health and Menzies School of
Health Research Human Research Ethics Committee
(HREC2015–2413) and the Mater Hospital Brisbane Hu-
man Research Ethics Committee (HREC15MHS55). All
procedures were in accordance with the ethical stan-
dards of the institutional and/or national research com-
mittee and with the 1964 Helsinki declaration and its
later amendments or comparable ethical standards. In-
formed consent was obtained from all individual pro-
viders included in the study. No quotes were labelled to
ensure the anonymity of all providers included in the
study was upheld.
Results
A total of 18 interviews were undertaken with a range of
healthcare providers including: senior registrar (n = 1),
medical consultant (n = 1), nurses (n = 4), pharmacists
(n = 3), Aboriginal liaison officers (n = 2), senior social
worker (n = 1), physiotherapists (n = 2), pastoral care
workers (n = 3) and a clinical nurse consultant (n = 1).
Of those interviewed, 15 were female (83%), three were
indigenous Australian (17%), and most (n = 12) had been
employed 4+ years in their current role.
Six key themes were identified relating to the study
aims: concern about risks using T&CM; no ‘real’ benefits
of T&CM; perception of T&CM and conventional medi-
cine as antithetical; barriers to disclosure; ‘patients’
choice’ is a double-edged sword, and; providers’ lack of
knowledge of Traditional indigenous Medicine.
Concern about risks associated with using T&CM
A common thread throughout the interviews was a con-
cern about potential risks of using T&CM in conjunc-
tion with conventional cancer treatments. Specifically,
health care providers mentioned interaction effects be-
tween drug-herb and drug-nutrient substances, as well
as compounding effects of using nutrients or herbs that
perform the same action as a drug. One provider illus-
trates this common concern around interactions, after
explaining that her cancer patients mainly use vitamins
and herbs “Usually when I admit a patient I ask “Did
you bring any tablets with you? or over the counter …
prescription?” because we have to know [in case of] some
sort of interaction with medication, even [if the tablets]
are natural but still [not] safe to give it [with the] medi-
cation prescribed.”
One compounding effect that was mentioned by sev-
eral providers was of fish oil thinning the blood. Several
providers stated that they recommend patients stop
using fish oil before surgery, as when compounded with
the use of drug-based blood thinners, the risk of bleed-
ing increases. However, one provider explained that she
assumes that the patient’s general practitioner will
already have discussed this with the patient before com-
ing to hospital, so she does not usually raise it.
“So even things like fish oil, if you take fish oil we say,
stop that seven days before you have an operation,
because it can thin the blood.”
“I would be concerned especially most of our surgical
patients they are on blood thinners post-surgery and
things like that. I would be concerned if that would
interfere … it would further thin the blood as well and
increases their risk of bleeding.”
There was also a reported lack of evidence available to
providers about the nature, efficacy, risks and benefits of
T&CM. Several providers explained that this makes it
difficult to determine what position to take on the use of
T&CM: “… it’s very hard because there is not a lot of lit-
erature in terms of drug interactions which is … my main
concern …. It depends on what the complementary medi-
cine was and if there was evidence to support stopping or
starting or continuing that would help to guide my deci-
sion …” . Another provider reiterates this reliance on evi-
dence-based medicine by stating: “… We just stick to
evidence-based medicine.”
This focus on risk overshadows the potential benefits
of T&CM, illustrated by the comment: “… the truth of
the matter is we probably have no interest, that’s awful,
but the medical structure has no interest in anything that
isn’t either a form of ingestion or topically that could
affect you or interact … we’re only concerned with the
things that will influence what we’re doing for the pa-
tient, not exactly holistic but that’s it.”
No ‘real’ benefits associated with T&CM
When asking providers about benefits to patients using
T&CM, responses were mixed, with some giving a de-
tailed response and others simply stating they did not
know of any benefits. Of those that gave detail of the
benefits of T&CM, an incongruity in their views was
evident. While several providers spoke of benefits to
mood, emotions, self-esteem and sense of control, these
Gall et al. BMC Complementary and Alternative Medicine          (2019) 19:259 Page 4 of 9
positives were couched in language suggestive that these
‘benefits’ were merely placebo effects and had no ‘real’
effects on the cancer itself.
“I’ve got vague ideas that the actual traditional
cultural meanings, people get benefits from that just
because they’re engaging in their culture. I’ve heard
of this before but I don’t know any physiological
reasons other than – more along the – not placebo,
but along those lines that can be helpful to people
because they feel like they’re taking ownership,
doing something for themselves, and it’s more along
those kind of lines. But that’s all I know; this vague
idea of, it helps them because they’re doing
something for themselves.”
While another provider immediately responds to the
question of benefit “No” followed directly after with
“Only emotionally, or spiritually, she’s complete” illustrat-
ing the common distinction between ‘real’ benefits in
fighting the cancer and the lesser valued benefits to
emotional wellbeing. As one provider reports, “I think
the best [benefit] would be a sense of control in decision
making and being responsible for their own health and
trusting what they know.”
This distinction between ‘real’ benefits of conventional
medicine and ‘placebo’ benefits of T&CM was under-
pinned by the perceived lack of evidence and providers’
lack of knowledge about T&CM, which greatly influence
providers’ opinions of T&CM.
Common perception of T&CM and conventional medicine
as antithetical
Another common theme embedded in the language of
the providers was that T&CM and conventional medi-
cine are discrete, antithetical concepts. One provider
alluded to this, firstly referring to anything the patient
takes that is not conventional medicine as being “un-
usual” then elaborating “I’m not really a fan of mixing
herbal with our regular medication.” The language of
unusual versus regular is suggestive of a right versus
wrong conception of these paradigms. Another pro-
vider gave a positive interpretation of this difference:
“I think it’s just a mindfulness of people treating them.
That they do have different traditions and beliefs.
And I think that they should be also explored and ac-
cepted from the team treating them.”
Barriers to disclosure
Providers were asked about talking with patients
about T&CM and whether they found patients to be
open to discussing T&CM. Providers who thought pa-
tients were open to discussing T&CM, described that
rapport must be established to achieve a willingness
to disclose. One provider responded: “[patients are
open about T&CM use] if asked the right way. And I
tend to – specifically if I am with an indigenous pa-
tient and I am doing a medication history interview, I
like to establish rapport first …” . In contrast, among
those providers who did not discuss T&CM with pa-
tients, there was a common sense of not wanting to
know. A few providers stated that it is “not my role”,
with one nurse referring patients to other providers if
the patient spontaneously disclosed T&CM use: “If
they ever mention to me [T&CM use] I will always
actually ask them to consult with their treating team
…” . One provider spoke about patients’ reluctance to
disclose their T&CM use for fear of disapproval,
which is a possible barrier to disclosure: “… they see
a hospital as very western medicine and therefore not
open to other views and often people will not – they
don’t tell the doctor they’re even on medications or
they’re on minerals, vitamins, whatever, they won’t tell
them because they think that we would disapprove
and that happens”. When considering TM specifically,
two providers alluded to a concerning issue where the
lack of provider knowledge of TM, coupled with the
likelihood that patients would not disclose anything
they see as irrelevant to conventional treatment, likely
results in self-perpetuating non-disclosure of patients
and unawareness of providers: “… they’re always
asked but whether they would actually consider what
they’re, say, singing and chanting, would they consider
that as part of what we’re expecting …” .
‘Patients’ choice’ is a double-edged sword
The idea that it is the patients’ choice whether they
choose to use T&CM is a complex and value-laden
issue, which was illustrated throughout the provider in-
terviews. The concept of choice presented itself as a
double-edged sword; on one hand providers spoke of the
positive aspects of T&CM use being empowering for the
patient, while on the other hand providers viewed that
by engaging in non-conventional medicines, the patient
was exposing themselves to risks outside of the control
of the mainstream providers. The inability to control
these risks for patients was clearly a concern for pro-
viders, however, the rights of the patient to make their
own determination was acknowledged by several
providers.
“We explain our medical point of view, if they want
to go off and try alternative medicines we accept
that that’s their choice and they have control over
their health and if they turn to – want to return, if
that medicine has failed and they want to come
back we – they are always welcome and we treat
them then if we can.”
Gall et al. BMC Complementary and Alternative Medicine          (2019) 19:259 Page 5 of 9
“It’d be like me saying you can’t have chemo
medication, it’s not my place, it’s the patients. If that
patient had made that – had gone to her family, and
they’ve gone to do that [engaged in T&CM use], that’s
the family business.”
One provider had a very strong response throughout her
interview in regard to cannabis/marijuana use for symp-
tom relief as being a patient’s choice, stating several
times throughout the interview that “I have no judge-
ment or opinion on it.” Another provider echoes this
view when they stated: “… we have a lot of cancer pa-
tients [that] tend to seek the alternative medicine, a lot of
them with the cannabis oil at the moment, that’s a big,
big way that a lot of people are going; if that’s their
choice, that’s their choice.”
Further complicating this concept of choice is the per-
ceived chasm between T&CM and conventional medi-
cine that is apparent in all the interviews with providers,
with one provider stating they know what is ‘best’ for
the patient, and putting the onus on the patient to make
the right choice in the eyes of the provider: “we suggest
what’s best, most appropriate, depends on patient accept-
ance, I suppose, what they would take as the recommen-
dation”. This assumption that conventional medicine is
the ‘best’ choice and that the patient is expected to
‘accept’ this is the underlying premise of evidence-based
medicine that underpins the reported views in all of the
interviews with providers. When this assumption is
coupled with the perceived ‘otherness’ of T&CM, it is
easy to see how the use of T&CM comes to be regarded
by providers as risky and potentially hazardous.
Providers’ lack of knowledge and understanding of
Traditional indigenous medicine
All providers’ self-reported their knowledge and under-
standing about CM was varied, and the non-indigenous
providers reported they had very little to no knowledge
of or understanding of TM.
“I know nothing about the Aboriginal traditional
medicines”
“I even don’t know what they are”
“The only thing I’ve seen here is people burn different
oils down here – because we have burners in all of our
rooms. That’s it, I don’t know if that’s a tradition they
they’re doing, or is it just ‘cause we have a burner and
they go, “Oh, that would be nice to do that.” So, I don’t
know anything in particular.”
One of the three indigenous providers, that all self-re-
ported having knowledge about TM, elaborated on the
lack of widespread understanding of TM among other
providers: “I’d suspect that my colleagues would not
know a lot about bush medicines or the fact of singing
and smoking ceremonies and things like that, I don’t
think they would appreciate that that is part of a healing
treatment option that indigenous patients might use …”.
The fact that providers reported generally knowing
less about TM than CM, suggests that they would be un-
likely to recognise or be aware if indigenous patients’
were using TM as part of their cancer-care. One pro-
vider alluded to the reasons for the lack of knowledge
around TM when she stated: “… my knowledge is lacking
… it’s too time consuming to go and investigate trad-
itional medicines as well, you know...” indicating they
only have time to concentrate on conventional medicine
as part of their role.
Discussion
To our knowledge, no previous research has explored
health provider’s experiences of and attitudes towards
indigenous Australian cancer patients’ T&CM usage and
disclosure. Our findings suggest there is a commonly
held perception that T&CM and conventional medicine
are oppositional rather than complementary in nature,
which is reflected in the knowledge, understanding and
perspectives about T&CM of the healthcare providers.
Most providers in this study conceded they have little
knowledge about T&CM, with their main concerns re-
lating to the potential negative interactions when used
concurrently with conventional cancer treatments. There
was an evident disconnect between the evidence-based
approach of the providers interviewed, and the holistic
benefits that T&CM can confer to patients. Some pro-
viders reported the view there are no ‘real’ benefits of
T&CM use, likening its effects to a placebo. However,
this overlooks some important non-physiological bene-
fits that T&CM provides, such as patient involvement in
decision making and the benefits of practicing and en-
gaging in culture, which have been shown as beneficial
in building the self-efficacy of patients [18].
Providers cite the lack of evidence around T&CM as
reasoning for their lack of knowledge and wariness sur-
rounding the use of T&CM. Research suggesting pos-
sible usage and self-reported benefits of T&CM in
cancer is emerging [34, 35] however, strong evidence re-
mains limited. Moreover, some providers stated they do
not have the time to seek out the evidence and/or feel
that T&CM is not part of their role, which further
widens the separation of T&CM and conventional medi-
cine. Interestingly, indigenous providers, while still con-
cerned about potential risks, revealed a greater depth of
understanding and knowledge of T&CM, especially con-
cerning TM. This may in part be owing to their cultural
and personal understanding of the differences in health
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paradigms adhered to by indigenous people and that of
conventional medicine [36, 37]. This greater depth of
understanding was reflected in their responses around
communication, explaining how they use rapport build-
ing in the first instance to facilitate open responses from
their patients. Similarly, non-indigenous providers who
also cited rapport building as an important first step to
communication also felt their patients were more open
about their T&CM use. These results infer that open
communication may be achieved through building rap-
port and providing a safe environment for the patient,
which may in turn increase the disclosure of T&CM.
Our findings support the findings of previous studies
involving non-Indigenous cancer patients that concerns
around potential risks contributes to the divide between
providers who support T&CM use and integration with
conventional medicine, and those who do not [23–25].
Broom and Adams found that oncology consultants used
their perceived risk of CM as a means to discourage its
use by their patients, although the consultants indicated
they had little knowledge of CM or the risks [25]. Fur-
thermore, oncology nurses saw themselves as CM advo-
cates, although this was discouraged by the oncology
consultants. Due to their lack of knowledge of risks asso-
ciated with CM use, they found the providers’ individual
beliefs about CM led to their decision to discourage its
use. Indeed, Shorofi and colleagues found a positive as-
sociation between nurses’ knowledge and their attitudes
towards CM, further showing this link between individ-
ual’s beliefs about CM and their attitude towards it [38].
The importance of open and effective patient-clinician
communication is paramount in modulating the poten-
tial risks and benefits associated with the use of T&CM
in the cancer setting [25, 26]. Previous studies have iden-
tified several factors that hinder patient-clinician com-
munication in regards to indigenous patients [26, 31].
For example, in a 2016 study conducted by Meiklejohn
et al., they found that the main barriers to cancer care
for indigenous people were related to challenges with
communication, the health system and coordination of
care, issues around individual and community priorities
and views of cancer treatment and health professional
judgement [26]. However, while these different factors
may be present in the current setting, our findings sug-
gest that the large divide in health paradigms and gen-
eral lack of provider’s understanding and knowledge of
T&CM, contribute to communicative discord in the
present group.
As with any study, this study has some strengths and
limitations. The inclusion of a range of providers in-
volved in cancer-care for indigenous patients from a
large urban hospital strengthens these findings; however
our limitations are that these results may not be repre-
sentative of all providers, both in and out of the cancer-
care setting and these findings may not be representative
of providers in rural and remote locations.
Conclusions
Given the possible usage of T&CM by Indigenous cancer
patients, our findings suggest that the limited under-
standing of healthcare providers of the risks, benefits
and usage of T&CM among their patients, should be ad-
dressed in order to inform discussion and disclosure
around this topic. Furthermore, providers need to be
mindful of creating a safe space for disclosure by helping
the patient feel comfortable when asking the question
about T&CM use. Our findings suggest this may be
achieved through initial and ongoing culturally-compe-
tent rapport building. In addition to building a stronger
evidence base on the efficacy and risks associated with
T&CM use in cancer-care, clinical practice would bene-
fit through research investigating indigenous patients’
experiences and perspectives of as well motivations for
using T&CM.
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